Abstract
Eleven lipids have been tested for cytotoxic (trypan blue dye exclusion) activity in cells from eight freshly explanted human leukemias in vitro. 4-Aminomethyl-1-[2,3-(di-N-decyloxy)N-propyl]-4-phenylpiperidine (CP-46,665), 1-mercapto-hexadecyl-2-methoxymethyl-rac-glycero-3-phosphocholine (BM 41.440), the 2-acetamide analog of platelet-activating factor (PAF) and 1-O-octadecyl-2-O-methyl-rac-glycero-3-phosphocholine (ET-18-OCH3) were found among the most active compounds. 2-Lysophosphatidylcholine (2-LPC) showed the lowest activity. However, in addition there was variation among the results regarding the activity of the 1-octadecyl-rac-glycero-3-phosphocholine (ET-18-OH) and its D- and L-forms, but a significantly higher cytotoxic activity of D-ET-18-OH compared with L-ET-18-OH on the basis of 2-LPC as control after an incubation time of 48 hr. We conclude that with the limited number of structures available, this type of study is not sufficient to yield further information about the mode of the accumulation and toxicity of this type of lipids.
Similar content being viewed by others
Abbreviations
- ALP:
-
alkyl lysophospholipid derivative(s)
- 2-LPC:
-
2-lysophosphatidylcholine
- ANLL:
-
acute non-lymphoblastic leukemia
- ALL:
-
acute lymphoblastic leukemia
- CML/BC:
-
chronic myeloid leukemia/blast crisis
- PAF:
-
platelet-activating factor
- CP-46,665:
-
4-aminomethyl-1-[2,3-(di-N-decyloxy)N-propyl]-4-phenyl-piperidine
- BM 41.440:
-
rac-1-mercapto-hexadecyl-2-methoxymethyl-rac-glycero-3-phosphocholine
- ET-18-OH:
-
1-O-octadecyl-rac-glycero-3-phosphocholine
- ET-18-OCH3 :
-
1-O-octadecyl-2-O-methyl-rac-glycero-3-phosphocholine
- ET-18-H:
-
1-O-octadecylpropane-3-phosphocholine
- ET-12-H:
-
1-O-dodecylpropanediol-3-phosphocholine
References
Berdel, W.E., Andreesen, R., and Munder, P.G. (1985) inPhospholipids and Cellular Regulation (Kuo, J.F., ed.) Vol. 2, pp. 41–73, CRC Press, Inc., Boca Raton, FL.
Andreesen, R., Modolell, M., Weltzien, H.U., Eibl, H., Common, H.H., Loehr, G.W., and Munder, P.G. (1978)Cancer Res. 38, 3894–3899.
Long, R.C., Small, W.C., Brynes, R.K., Tidwell, T., Goldstein, J.H., and Vogler, W.R. (1983)Cancer Res. 43, 770–775.
Tidwell, T., Guzman, G., and Vogler, W.R. (1981)Blood 57, 794–797.
Berdel, W.E., Fink, U., Egger, B., Reichert, A., Munder, P.G., and Rastetter, J. (1981)J. Natl. Cancer Inst. 66, 813–817.
Runge, M.H., Andreesen, R., Pfleiderer, A., and Munder, P.G. (1980)J. Natl. Cancer Inst. 64, 1301–1306.
Berdel, W.E., Von Hoff, D.D., Unger, C., Schick, H.D., Fink, U., Reichert, A., Eibl, H., and Rastetter, J. (1986)Lipids, 21, 301–304.
Hoffman, D.R., Hajdu, J., and Snyder, F. (1984)Blood 63, 545–552.
Berdel, W.E., Schick, H.D., Fink, U., Reichert, A., Ulm, K., and Rastetter, J. (1985)Cancer Res. 45, 1206–1213.
Author information
Authors and Affiliations
About this article
Cite this article
Danhauser, S., Berdel, W.E., Schick, H.D. et al. Structure-cytotoxicity studies on alkyl lysophospholipids and some analogs in leukemic blasts of human origin in vitro. Lipids 22, 911–915 (1987). https://doi.org/10.1007/BF02535553
Received:
Issue Date:
DOI: https://doi.org/10.1007/BF02535553